The Alliance for Regenerative Medicine Announces Fourth Annual Cell & Gene Therapy Investor Day & Initial Slate of Presenting Companies

– February 2, 2016

WASHINGTON, D.C., February 2, 2016 – The Alliance for Regenerative Medicine (ARM) today announced its annual Cell & Gene Therapy Investor Day will take place March 22, 2016 in New York City. The event is co-hosted by leading investment banking firm Piper Jaffray.

“Our sector is poised for a number of significant scientific and clinical breakthroughs in the very near term,” said Edward Lanphier, ARM chairman and president and CEO of Sangamo BioSciences. “Cell, gene and other regenerative medicine therapies offer the investment community the exciting opportunity to participate in the growth of this disruptive new area and the development of novel therapeutics to address unmet medical needs in a range of indications.”

This year’s Cell & Gene Therapy Investor Day will feature presentations by more than 30 leading companies developing advanced therapies. In addition, life science investment analysts and clinical and commercial leaders will discuss the potential for cell, gene and immunotherapies to impact the standards of care in key therapeutic areas, such as oncology, ophthalmology, neurodegenerative diseases, diabetes and cardiovascular diseases.

Presenting Companies:
4D Molecular Therapeutics, AGTC (AGTC), Argos Therapeutics (ARGS), Athersys (ATHX), Avalanche Biotechnologies (AAVL), Bellicum Pharmaceuticals (BLCM), BioLife Solutions (BLFS), bluebird bio (BLUE), Capricor Therapeutics (CAPR), Celyad (CYAD), Fate Therapeutics (FATE), Fibrocell Science (FCSC), GenSight, Histogenics (HSGX), Inovio Pharmaceuticals (INO), Lion Biotechnologies (LBIO), Mesoblast (MESO), Osiris Therapeutics (OSIR), Oxford BioMedica (OXB.L), Pluristem Therapeutics (PSTI), ReNeuron (RENE), Sangamo BioSciences (SGMO), uniQure (QURE), Voyager Therapeutics (VYGR)

The program’s initial slate of presenting companies was selected on the basis of upcoming key milestones, innovative technologies and investor validation. Additional companies will be announced in the coming weeks.

In addition to the event’s co-host Piper Jaffray and supporting bank, Maxim Group, sponsors include BioLife Solutions; Kawasaki; Lonza; and PCT, a Caladrius company. For more information please visit the event’s website at Credentialed investors, life science strategic partners and members of the media can indicate their interest in attending here.

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 230 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit

# # #